Based on this evidence, GLS1 inhibitors (e.g., CB-839) that are being investigated to inhibit glutamine utilization in cancer cells could potentially hamper the activation of antitumor immunity through the inhibition of glutamine metabolism in both T cells and macrophages [124,125,126,127]. The gene discussed is GLS; the disease is cancer.